Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?

• Autors principals: Sviatoslav Chekhun (Autor), Assumpció Lopez-Paradís (Autor), Aintzane Urbizu (Autor), Teresa Morán (Autor), Anabel Mañes (Autor), Marc Cucurull (Autor), Carlos Martínez-Barenys (Autor), Iris Teruel (Autor), Gloria Moragas (Autor), Enric Carcereny (Autor), Ana Maria Muñoz Mármol (Autor), Maria Saigí (Autor)
• Format: Llibre
• Publicat: Open Exploration Publishing Inc., 2023-12-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown impressive results in EGFR mutant lung cancer (LC) patients in terms of disease control rate with a positive impact on overall survival. Nevertheless, after months of treatment with targeted therapy...